User:Mr. Ibrahem/Pexidartinib

Pexidartinib, sold under the brand name Turalio, is a medication used to treat tenosynovial giant cell tumor (TGCT). It is used in cases which result in significant problems and cannot be treated by surgery. It is taken by mouth.

Common side effects include liver problems, loss of hair color, tiredness, low neutrophils, increased cholesterol, eye swelling, and rash. The liver problems can result in death. Use in pregnancy may harm the baby. It is a kinase inhibitor and works by blocking colony-stimulating factor-1 receptor (CSF-1R).

Pexidartinib was approved for medical use in the United States in 2019. It was refused approval in Europe in 2020 due to minimal benefits and concerns regarding side effects. It is not approved in the United Kingdom. In the United States it costs about 21,200 USD per month.